The market for complex therapies that train living cells to attack cancer is taking baby steps, but there’s still a lot of enthusiasm for experimental drugs coming through the pipeline from bluebird bio and it’s big biotech partner Celgene .
That enthusiasm fell a notch after Amgen released exciting data from a handful of patients that suggests it’s found a much easier way to achieve the same goal.